Brief: Abivax Announces Presentation Of Late-Breaking Abstract For Obefazimod From Abtect Phase 3 Induction Trials At 2025 UEG Meeting
23/09/2025 23:29
Sept 23 (Reuters) - Abivax SA ABVX.PA: ABIVAX ANNOUNCES PRESENTATION OF LATE-BREAKING ABSTRACT FOR OBEFAZIMOD FROM THE ABTECT PHASE 3 INDUCTION TRIALS AT 2025 UNITED EUROPEAN GASTROENTEROLOGY (UEG) MEETING Source text: ID:nGNX12byyG Further company coverage: ABVX.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abivax SA
See all newsAbivax shares fall after rival drug data, trader says
France's Abivax H1 net loss widens on higher expenses driven by clinical programs
U.S. RESEARCH ROUNDUP-Caseys General Stores, Targa Resources, United Rentals
GS starts Abivax at 'buy,' sees multibillion sales potential for lead drug candidate
Europe's STOXX 600 ends week at all-time high on earnings support, soft US jobs data